Published · Aurelis Peptides
Tesamorelin and ipamorelin appear in growth-hormone discussions because both have been studied in relation to its release. They have different molecular identities and signalling backgrounds. A useful comparison connects each name to the research question, the measurement and the material actually listed.
Here, we compare a tesamorelin study measuring abdominal and liver fat with an ipamorelin study measuring blood concentrations and growth-hormone response. This helps separate a body-composition finding from a short-term hormone measurement.
Tesamorelin vs ipamorelin at a glance
| Compare | Tesamorelin | Ipamorelin |
|---|---|---|
| Molecular identity | Modified 44-amino-acid GHRH analogue | Synthetic five-amino-acid peptide |
| Research pathway | Growth-hormone-releasing hormone | GHRP / ghrelin-receptor pathway |
| Selected human study | Abdominal and liver fat over six months | Peptide concentrations and growth-hormone response |
| Current Aurelis entry | Tesamorelin 5 mg / 10 mg per unit | Ipamorelin + CJC (no DAC) |
| Specification to confirm | Selected content and presentation | Both components, amounts, total and ratio |
GHRH and ghrelin: similar names, separate signals
GHRH means growth-hormone-releasing hormone. Tesamorelin is a modified version of its 44-amino-acid chain. The original TH9507 research describes that molecular modification. Work on the human GHRH receptor shows how this releasing-hormone signal is recognised by cells. Tesamorelin development study · Human GHRH receptor study.
Ipamorelin is a pentapeptide: a chain of five amino acids. Its discovery study identified GHRP-like receptor activity using receptor-blocking experiments. Later original work describes ipamorelin acting through the ghrelin receptor in a rodent gastric-motility model. These studies identify its research pathway; they do not test the Aurelis blend. Ipamorelin discovery study · Ghrelin-receptor research.
The practical distinction is the signal being investigated. Sharing an interest in growth hormone does not make two peptide sequences interchangeable. A comparison should retain the full molecule name rather than collapse both into a generic growth-hormone label.
What did the tesamorelin fat study measure?
Stanley and colleagues enrolled 50 adults with HIV, receiving antiretroviral treatment, who had accumulated abdominal fat. Their 2014 randomised, double-blind trial compared tesamorelin with placebo over six months. The main measurements were visceral fat and liver fat.
Visceral fat means fat around the internal organs. The mean change in its measured area was −34 cm² with tesamorelin versus +8 cm² with placebo. Liver-fat measurements also decreased more in the tesamorelin group. The report noted an early fasting-glucose increase; the between-group glucose changes at six months were not significant. Read the primary 2014 trial.
The area change is not kilograms lost or a percentage of total body weight. These findings concern the studied participants and clinical preparation. They cannot be converted into a general weight-loss result or used to verify an Aurelis catalogue batch.
What did the human ipamorelin study measure?
Gobburu and colleagues studied healthy male volunteers in 1999. They measured ipamorelin and growth-hormone concentrations in blood, then modelled the relationship between them. Pharmacokinetics describes how a substance moves through the body; pharmacodynamics describes the measured response.
The study reported an episode of growth-hormone release followed by declining concentrations. Variation in the response between individuals was greater than variation in the peptide's pharmacokinetic measurements. Its purpose was to characterise that concentration-response relationship. Read the human ipamorelin study.
A blood-hormone response and a scan-measured change in fat are different endpoints. These selected papers did not compare tesamorelin against ipamorelin, and the ipamorelin experiment did not test long-term fat loss or the combined Ipamorelin + CJC presentation.
Ipamorelin vs tesamorelin: catalogue differences
Aurelis lists Tesamorelin 5 mg / 10 mg per unit. Those figures describe listed content. They do not describe a delivered dose, liquid concentration or the preparation used in a published trial. See our content and concentration guide for the unit distinction.
Ipamorelin appears in Ipamorelin + CJC (no DAC), with the complete specification on request. There is no current standalone Ipamorelin entry. The source does not settle the CJC amount, combined total or component ratio. Request a full formulation before comparing quantities.
For a comparison involving sermorelin, use the separate Tesamorelin vs Sermorelin and Ipamorelin vs Sermorelin guides. Each addresses that third peptide. Our CJC DAC and no-DAC guide explains the additional naming question in the blend.
Request the right vial or kit details
Both vials and pen-style kits remain available presentation enquiries. Include the full entry name, selected listed content or blend specification, quantity, preferred format and destination in Australia, Canada or the USA. Ask the team to confirm local availability for the actual proposal.
Request matching identity, content and batch documents, plus the complete packaging specification. Send a Tesamorelin or Ipamorelin + CJC enquiry, or email sales@aurelispeptides.com.
Primary research sources
- Ferdinandi et al., Basic & Clinical Pharmacology & Toxicology, 2007 — TH9507 molecular identity and non-clinical development.
- Gaylinn et al., Molecular Endocrinology, 1993 — human GHRH receptor research.
- Raun et al., European Journal of Endocrinology, 1998 — ipamorelin identity and receptor-pathway experiments.
- Greenwood-Van Meerveld et al., Journal of Experimental Pharmacology, 2012 — ipamorelin and ghrelin-receptor mechanisms in a rodent model.
- Stanley et al., JAMA, 2014 — visceral and liver-fat endpoints in adults with HIV.
- Gobburu et al., Pharmaceutical Research, 1999 — human ipamorelin concentrations and growth-hormone response.